



Public Health
England

Protecting and improving the nation's health

Rapid assessment of the Seegene 'Allplex 2019-nCoV' assay for the detection of SARS-CoV-2 (COVID-19)

V01.20. Uncontrolled when printed or downloaded

Current version available at: <https://www.gov.uk/government/publications/covid-19-phe-laboratory-assessments-of-molecular-tests>

About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. We do this through world-leading science, research, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support.

Public Health England

Wellington House

133-155 Waterloo Road

London SE1 8UG

Tel: 020 7654 8000

www.gov.uk/phe

Twitter: [@PHE_uk](https://twitter.com/PHE_uk)

Facebook: www.facebook.com/PublicHealthEngland

Prepared by NIS Laboratories, National Infection Service, Public Health England



© Crown copyright 2020

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](https://www.ogilive.gov.uk). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published June 2020

PHE publications

gateway number: GW-1316

PHE supports the UN

Sustainable Development Goals



Rapid assessment of the Seegene 'Allplex 2019-nCoV' assay for the detection of SARS-CoV-2 (COVID-19)

Introduction

The emergence of the SARS-CoV-2 virus in humans and spread of the associated disease, COVID-19, has been declared a Public Health Emergency of International Concern by the World Health Organization (WHO). In the UK, the deployment of a PHE in-house real-time PCR assay in PHE, PHE collaborating laboratories as well as in Devolved Administrations is being followed up with assessments of commercially developed and provided diagnostic tests for SARS-CoV-2 detection.

This assessment examined the Seegene 'Allplex 2019-nCoV' assay (SeeGene #RP10244Y (50 rxn & #RP10243X 100 rxn), targeting SARS-CoV-2 RdRp and N genes.

The assessment panel

The assessment sample-panel totalled 195 specimens, including respiratory clinical specimens negative for SARS-CoV-2 as determined by the validated in-house PHE PCR assay and 3 dilutions of material positive for SARS-CoV-2 tested in duplicate. Statistical assessment of panel sizes determined that when the measured specificity for 195 samples is 100% that the true specificity of the test is at least 98.1%.

Performing and analysing the assay

Nucleic acid extracts were added to aliquoted RT-PCR mastermix according to the manufacturer's instructions in batches of up to 94 samples, plus a positive and negative control. Amplification was performed using the BioRad CFX 96 RT-PCR instrument according to the manufacturer's instructions. Initial data analysis was performed in the CFX96 Manager software prior, followed by export to the Seegene viewer software.

The SARS-CoV-2 results were automatically categorised by the 'Seegene viewer' software as '2019-nCoV detected', 'negative' or 'invalid' based on predefined parameters (Allplex 2019-nCoV assay IFU). The automated calls were confirmed visually and agreed between 2 Clinical Scientists.

Results

From a challenge with positive material, all samples for a 3-step dilution series were found positive for SARS-CoV-2.

Compared with the results from the PHE COVID-19 assay the following was found:

	Samples (n)	True positive	False positive	True negative	False negative	Negative percentage agreement
Seegene 'Allplex 2019-nCoV'	195	0	0	195	0	100% (195/195)

Report date

A version of the report was distributed by PHE's COVID-19 Incident Virology Cell on 13/03/2020.

Disclaimer

PHE's assessments of commercial products for diagnosing COVID-19 infection have been carried out primarily for PHE's own use and under agreement; the reports of such assessments are shared solely for the readers' information; PHE does not in any way recommend any particular COVID-19 diagnostic assay or extraction platform; PHE shall not be responsible for any choice of COVID-19 diagnostic assay or extraction platform, and it is the testing laboratory's responsibility to ensure that any such assay or platform implemented has undergone the necessary verification and validation; and PHE shall not be liable, to the greatest extent possible under any applicable law, for any claim, loss or damage arising out of or connected with the use of this and related reports and any choice of COVID-19 diagnostic assay products or extraction platforms.

A position statement regarding COVID-19 tests evaluated by PHE is available at: <https://www.gov.uk/government/publications/position-statement-regarding-covid-19-tests-evaluated-by-phe>

Further information

Queries about our assessments of SARS-CoV-2 (COVID-19) diagnostics should be sent to labvalidation.cov@phe.gov.uk

Table of changes

Date	New version no.	Details of changes
27/04/2020	1.2	Changes to disclaimer
27/04/2020	1.2	Consistency for use of the term "assessment"
27/04/2020	1.2	Tables of changes added
12/05/2020	1.2	Change of template
12/05/2020	1.2	Version number and website added (footer)
12/05/2020	1.2	Addition of date reported by Virology Cell
26/05/2020	1.2	Minor changes for consistency with other reports